Samsung Biologics Wins 'CDMO Leadership Awards' for 12 Consecutive Years

First Korean Company to Win for 12 Consecutive Years
Proving CDMO Leadership with Global Category Award

Samsung Biologics announced on the 19th (local time) that it received an award at the 'CDMO Leadership Awards' held in New York, USA. James Choi, Vice President of Sales Support (left), and Kevin Sharp, Vice President of Sales & Operation, along with other Samsung Biologics officials, are taking a commemorative photo after receiving the award. Photo by Samsung Biologics

Samsung Biologics announced on the 20th that it has won the 'CDMO Leadership Awards,' a globally prestigious contract development and manufacturing organization (CDMO) ceremony, for 12 consecutive years?the first domestic company to achieve this.

The CDMO Leadership Awards is a global ceremony jointly hosted by the pharmaceutical and bio industry research organization 'Outsourced Pharma' and the life sciences professional magazine 'Life Science Connect.' Customers who have actually collaborated with the nominated companies participate in the evaluation, making it an award that best reflects the industry's voice.

Starting this year, the award categories were subdivided by portfolio, such as Biologics and Cell & Gene Therapy, and within each field, companies were classified based on their production facilities and research bases into 'Global,' 'International,' and 'North America' regions.

Samsung Biologics won this year in the 'Biologics-Global' category, once again proving its world-class CDMO competitiveness. It is known that its overwhelming production capacity and innovative technology were highly evaluated.

Samsung Biologics continues to achieve high growth by setting record-breaking performance every year. Last year, it recorded annual sales of 4.5 trillion KRW for the first time in the domestic pharmaceutical and bio industry, and the cumulative annual order amount exceeded 5 trillion KRW. In addition, through proactive investment and diversification of its business portfolio, it is accelerating its leap to become a global top bio company.

In the CMO (contract manufacturing) sector, the company is constructing its 5th plant with a capacity of 180,000 liters, aiming for operation in April this year. Upon completion, the total production capacity will reach 784,000 liters, making it the largest in the world. Currently, plants 1 to 3 are operating at full capacity, and plant 4 is expanding production capabilities through continuous ramp-up.

In the CDO (contract development) sector, Samsung Biologics strengthened its portfolio competitiveness by launching a total of four technology platforms last year, including the high-concentration formulation development platform 'S-HiConTM' and the high-concentration cell culture development support platform 'S-TensifyTM.'

John Rim, CEO of Samsung Biologics, said, "The achievement of winning the CDMO Leadership Awards for 12 consecutive years is thanks to the strong trust of our customers," adding, "We will continue to expand our production capabilities to provide high-quality biopharmaceuticals and do our best to maximize customer satisfaction through innovative technologies and services."

Meanwhile, to broaden its contact points with global customers, Samsung Biologics will participate in the 'Festival of Biologics USA' held in San Diego, USA, in April, and the 'PEGS Boston Summit' held in Boston, USA, in May, following its participation in DCAT Week. Through participation in various global conferences, the company plans to promote its competitiveness and further strengthen its order activities.

This content was produced with the assistance of AI translation services.